Clinical Trials Browser

Interventional × Central Nervous System Diseases × pembrolizumab × Clear all

NCT04512261 2022-07-01

TOPAZ

Phase 1/2 Withdrawn

Brain Neoplasms, Breast Neoplasms, Central Nervous System Diseases